FDA to rule this week on Incyte's bid for wider use of Jakafi

John George
FDA to rule this week on Incyte's bid for wider use of Jakafi

The Food and Drug Administration is expected to rule late this week on Incyte Corp.’s effort to get a wide approval for its flagship Jakafi medication. Jakafi is already approved as a treatment for polycythemia vera, a chronic type of bone marrow disease, and for people with intermediate or high-risk myelofibrosi, a group of rare cancers of the bone marrow. GVHD is a condition that can occur after a patient receives a stem cell transplant from a donor.